Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma

Small molecular inhibitors targeting BRD4 family proteins are emerging as promising therapies in many types of human malignancies. However, whether BRD4, as well as other BET family members, may serve as therapeutic targets in renal cell carcinoma (RCC) remains unknown. In this study, we found that...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogenesis
Principais autores: Chen, Wei, Zhang, Hao, Chen, Zhifeng, Jiang, Hao, Liao, Liping, Fan, Shijie, Xing, Jing, Xie, Yiqian, Chen, Shijie, Ding, Hong, Chen, Kaixian, Jiang, Hualiang, Luo, Cheng, Zheng, Mingyue, Yao, Zhiyi, Huang, Yiran, Zhang, Yuanyuan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6212493/
https://ncbi.nlm.nih.gov/pubmed/30385738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0093-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados